| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014 | 2806 | 2014 |
| Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ... JAMA oncology 1 (5), 582-591, 2015 | 675 | 2015 |
| PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer SP Rowe, KJ Macura, E Mena, AL Blackford, R Nadal, ES Antonarakis, ... Molecular imaging and biology 18, 411-419, 2016 | 259 | 2016 |
| Small cell carcinoma of the prostate R Nadal, M Schweizer, ON Kryvenko, JI Epstein, MA Eisenberger Nature Reviews Urology 11 (4), 213-219, 2014 | 251 | 2014 |
| Management of metastatic bladder cancer R Nadal, J Bellmunt Cancer treatment reviews 76, 10-21, 2019 | 224 | 2019 |
| Short-term natural weathering of MSWI bottom ash JM Chimenos, AI Fernández, R Nadal, F Espiell Journal of Hazardous Materials 79 (3), 287-299, 2000 | 172 | 2000 |
| Biomarkers characterization of circulating tumour cells in breast cancer patients R Nadal, A Fernandez, P Sanchez-Rovira, M Salido, M Rodríguez, ... Breast Cancer Research 14, 1-12, 2012 | 122 | 2012 |
| CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy R Nadal, FG Ortega, M Salido, JA Lorente, M Rodríguez‐Rivera, ... International journal of cancer 133 (10), 2398-2407, 2013 | 117 | 2013 |
| Comparison of prostate-specific membrane antigen–based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic … SP Rowe, KJ Macura, A Ciarallo, E Mena, A Blackford, R Nadal, ... Journal of Nuclear Medicine 57 (1), 46-53, 2016 | 116 | 2016 |
| Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone DL Suzman, B Luber, MT Schweizer, R Nadal, ES Antonarakis The Prostate 74 (13), 1278-1285, 2014 | 108 | 2014 |
| Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors AB Apolo, R Nadal, DM Girardi, SA Niglio, L Ley, LM Cordes, ... Journal of Clinical Oncology 38 (31), 3672, 2020 | 101 | 2020 |
| Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel HH Cheng, R Gulati, A Azad, R Nadal, P Twardowski, UN Vaishampayan, ... Prostate cancer and prostatic diseases 18 (2), 122-127, 2015 | 100 | 2015 |
| EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer MJ Serrano, FG Ortega, MJ Alvarez-Cubero, R Nadal, P Sanchez-Rovira, ... Oncotarget 5 (17), 7486, 2014 | 89 | 2014 |
| Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration‐resistant prostate cancer: a retrospective study BL Maughan, B Luber, R Nadal, ES Antonarakis The Prostate 77 (1), 33-40, 2017 | 83 | 2017 |
| Bipolar androgen therapy for men with androgen ablation naive prostate cancer: results from the phase II BATMAN study MT Schweizer, H Wang, B Luber, R Nadal, A Spitz, DM Rosen, H Cao, ... The Prostate 76 (13), 1218-1226, 2016 | 80 | 2016 |
| Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC)(RADVAX RCC). HJ Hammers, D Vonmerveldt, C Ahn, RM Nadal, CG Drake, MR Folkert, ... Journal of Clinical Oncology 38 (6_suppl), 614-614, 2020 | 74 | 2020 |
| Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients … R Nadal, A Amin, DM Geynisman, MH Voss, M Weinstock, J Doyle, ... Annals of Oncology 27 (7), 1304-1311, 2016 | 74 | 2016 |
| Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer X Nogues, S Servitja, MJ Peña, D Prieto-Alhambra, R Nadal, ... Maturitas 66 (3), 291-297, 2010 | 72 | 2010 |
| Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial … RM Nadal, A Mortazavi, M Stein, SK Pal, NN Davarpanah, HL Parnes, ... Journal of Clinical Oncology 36 (6_suppl), 515-515, 2018 | 68 | 2018 |
| Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial AB Apolo, R Nadal, Y Tomita, NN Davarpanah, LM Cordes, SM Steinberg, ... The Lancet Oncology 21 (8), 1099-1109, 2020 | 67 | 2020 |
